An exploratory, randomised, placebo-controlled, 14 day trial of the soluble guanylate cyclase stimulator praliciguat in participants with type 2 diabetes and hypertension

Hanrahan, JP; Seferovic, JP; Wakefield, JD; Wilson, PJ; Chickering, JG; Jung, J; Carlson, KE; Zimmer, DP; Frelinger, AL; Michelson, AD; Morrow, L; Hall, M; Currie, MG; Milne, GT; Profy, AT

Hanrahan, JP (corresponding author), Cyclerion Therapeut Inc, 301 Binney St, Cambridge, MA 02142 USA.

DIABETOLOGIA, 2020; 63 (4): 733

Abstract

Aims/hypothesis Praliciguat (IW-1973), a soluble guanylate cyclase stimulator, amplifies nitric oxide signalling. This exploratory trial investigated ......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索